天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>6151-40-2

6151-40-2

中文名稱 奎寧定鹽酸鹽
英文名稱 QUINIDINE HYDROCHLORIDE
CAS 6151-40-2
分子式 C20H24N2O2.ClH.H2O
分子量 378.9
MOL 文件 6151-40-2.mol
6151-40-2 結(jié)構(gòu)式 6151-40-2 結(jié)構(gòu)式

基本信息

中文別名
奎尼丁鹽酸鹽
奎寧定鹽酸鹽
奎尼丁單鹽酸鹽一水合物
奎尼丁 鹽酸鹽 一水合物
英文別名
QUINIDINE HYDROCHLORIDE
QUINIDINE HYDROCHLORIDE MONOHYDRATE
Quinidine monohydrate hydrochloride
Quinidine monohydrochloride monohydrate
QUINIDINE HYDROCHLORIDE ISO 9001:2015 REACH
QUINIDINE HYDROCHLORIDE MONOHYDRATE CRYSTALLINE
6μ-Methoxycinchonan-9-ol hydrochloride monohydrate
Quinidine hydrochloride monohydrate technical grade
所屬類別
醫(yī)藥中間體:喹啉類化合物

物理化學(xué)性質(zhì)

熔點258-259 C
儲存條件-20°C儲存
溶解度DMSO: 100 mg/mL (263.93 mM); Water: 2.5 mg/mL (6.60 mM)
形態(tài)Solid
顏色White to off-white

安全數(shù)據(jù)

危險性符號(GHS)GHS hazard pictograms
GHS07
警示詞警告
危險性描述H302+H312+H332
危險品標(biāo)志Xn,Xi
危險類別碼20/21/22-36/37/38
安全說明36-26
危險品運輸編號UN 2811 6.1/PG 3
WGK Germany3
奎寧定鹽酸鹽價格(試劑級)
報價日期產(chǎn)品編號產(chǎn)品名稱CAS號包裝價格
2024/11/08HY-B1302奎寧定鹽酸鹽
Quinidine hydrochloride monohydrate
6151-40-2100mg500元
2024/11/08HY-B1302奎寧定鹽酸鹽
Quinidine hydrochloride monohydrate
6151-40-210mM * 1mLin DMSO550元

常見問題列表

生物活性
Quinidine hydrochloride monohydrate 是一種抗心律失常劑,也是 K+ 通道 (K+ channel) 的有效阻斷劑,其 IC50 值為 19.9 μM。Quinidine hydrochloride monohydrate 是一種有效且選擇性的細(xì)胞色素 P450db (cytochrome P450db) 抑制劑,也可用作瘧疾的研究。
靶點

IC50: 19.9 μM (K + channel)

體外研究

Quinidine hydrochloride monohydrate blocks WT mSlo3 (K Ca 5.1) channels with an IC 50 of 19.9±1.41?μM and Hill slope of 1.15±0.15 (n=7). Again, the potency of inhibition by Quinidine hydrochloride monohydrate is higher for F304Y mSlo3 (IC 50 of 2.42±0.60?μM, n=9, P<0.005; Hill slope of 0.98±0.12), but lower with R196Q mSlo3 (IC 50 of 38.4±6.77?μM, n=5, P<0.001; Hill slope of 1.05±0.16). The inhibition of F304Y mSlo3 by Quinidine hydrochloride monohydrate is observed to have some time dependence.

體內(nèi)研究

Direct application of Quinidine hydrochloride monohydrate on the sciatic nerve produces a dose-related decrease in amplitude at ascending somato-sensory evoked potential (SSEP) and descending compound muscle action potentials (CMAP) when comparing baseline with other time points, or when comparing the experimental left limb to the right contra-lateral glucose-treated limb. The latencies of SSEPs and CMAP potentials after Quinidine hydrochloride monohydrate applications are increased compare to baseline and the contralateral side.

"6151-40-2" 相關(guān)產(chǎn)品信息
628-13-7 60-93-5 142-04-1 593-81-7 593-51-1 130-95-0 118-10-5 56-54-2 24302-67-8